Is it necessary to receive the 13-valent vaccine?
May 25, 2022
Source: Cainiu Health
Dr. Zhang Weiling
Introduction
If financially feasible, vaccination is strongly recommended. The 13-valent vaccine is the 13-valent pneumococcal conjugate vaccine, which protects against infections caused by multiple serotypes of *Streptococcus pneumoniae*. Children under 5 years of age and adults over 60 have significantly weakened immune systems, rendering them highly susceptible to various pathogenic microorganisms; consequently, their risk of developing pneumonia due to *Streptococcus pneumoniae* infection is substantially increased.
The 13-valent pneumococcal conjugate vaccine (PCV13) is a self-funded vaccine. If financially feasible, vaccination is strongly recommended. PCV13 protects against infections caused by 13 specific serotypes of Streptococcus pneumoniae. However, it only prevents pneumococcal pneumonia caused by the serotypes included in the vaccine; it does not protect against pneumonia or otitis media caused by other S. pneumoniae serotypes or by other microorganisms.
Nonetheless, vaccination is especially critical for very young children, older children, and elderly individuals. Children under five years of age and adults aged 60 years and older have significantly weakened immune systems, rendering them highly susceptible to pathogenic microorganisms. Consequently, their risk of developing pneumococcal pneumonia is markedly increased—making PCV13 vaccination particularly important for these groups.
Parents are advised to choose PCV13 over the 7-valent (PCV7) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) for their infants because PCV7 offers narrower serotype coverage than PCV13, while PPSV23 provides only short-term protection in infants. Considering efficacy, duration of immunity, and overall suitability, PCV13 is the optimal choice for infant vaccination.
